← All trials
NCT06372964
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 13, 2024
- Primary completion
- Apr 30, 2027
- Completion date
- May 31, 2027
- First posted
- Apr 18, 2024
- Last posted
- Jul 29, 2024
- Enrollment
- 384
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Intra-Cellular TherapiesLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.